Research studies
Research for Bladder Cancer
-
- Cancer type: Bladder Cancer
- Principal Investigator: Dr Joachim Chan
- Project Acronym: MK-3475-905
- Study Title: A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
- Study Phase: Phase 3
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date: 16/02/2026
- Status: Open
-
- Cancer type: Bladder Cancer
- Principal Investigator: Dr Joachim Chan
- Project Acronym: RC48-G001
- Study Title: A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in Subjects with HER2-Expressing Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma
- Study Phase: Phase 2
- Sponsor: Seagen Inc.
- End Date:
- Status: Open
-
- Cancer type: Bladder Cancer
- Principal Investigator: Dr Joachim Chan
- Project Acronym: AURORA
- Study Title: Atezolizumab in patients with urinary tract squamous cell carcinoma:a single arm, open label, multicentre, phase II clinical trial
- Study Phase: Phase 2
- Sponsor: University Hospital Southampton NHS Foundation Trust
- End Date: 31/12/2025
- Status: Open
-
- Cancer type: Bladder Cancer
- Principal Investigator: Dr Joachim Chan
- Project Acronym: Rad-IO
- Study Title: A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer
- Study Phase: Phase 2/3
- Sponsor: University of Birmingham
- End Date: 03/06/2025
- Status: Open
-
- Cancer type: Bladder Cancer
- Principal Investigator: Georgiana Synesi
- Project Acronym: REPRESENT
- Study Title: Exploring Barriers to Recruiting Underrepresented Groups to Bladder and Head & Neck Oncology Trials: A Mixed-methods Approach to Increasing Representation
- Study Phase: Not Applicable
- Sponsor: Institute of Cancer Research
- End Date:
- Status: Open
Research for Blood Cancer
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Matt Wells
- Project Acronym: HoOP Study
- Study Title: Hodgkin Lymphoma in Older Patients (HoOP) - A Retrospective Study
- Study Phase: Not Applicable
- Sponsor: University of Oxford
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Nasim Ali
- Project Acronym: VIVO Biobank
- Study Title: VIVO Biobank Research Tissue Bank
- Study Phase:
- Sponsor: Newcastle University
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Nauman Butt
- Project Acronym: UK national retrospective data collection on outcomes of CML in pregnancy
- Study Title: UK national retrospective data collection on outcomes of CML in pregnancy
- Study Phase:
- Sponsor: Imperial College London
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Nauman Butt
- Project Acronym: POIESIS
- Study Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Versus Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib
- Study Phase: Phase III
- Sponsor: Kartos Therapeutics, Inc.
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Stella Williams
- Project Acronym: GLORA Study
- Study Title: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Study Phase: Phase III
- Sponsor: Ascentage Pharma Group Inc
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Dr Vikram Singh
- Project Acronym: ALMANAC
- Study Title: A real-world data and sample compendium of frail and/or multiply treated large B-cell lymphoma
- Study Phase: Not Applicable
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: Tazemetostat or placebo in combination with lenalidomide + rituximab for R/R FL
- Study Title: A phase 1B/3 double-blind, randomized, active-controlled, adaptive study of tazemetostat or placebo in combination with Lenalidomide plus Rituximab in participants with relapsed/refractory follicular lymphoma
- Study Phase: Phase III
- Sponsor: PAREXEL International
- End Date:
- Status: Open
-
- Cancer type: Blood Cancer
- Principal Investigator: Prof Nagesh Kalakonda
- Project Acronym: RADAR (Hodgkin Lymphoma)
- Study Title: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
- Study Phase: Phase III
- Sponsor: University College London
- End Date:
- Status: Open
Research for Brain Cancer
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Nicky Thorp
- Project Acronym: SIOP Ependymoma II
- Study Title: SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma
- Study Phase: Phase 2
- Sponsor: University of Birmingham
- End Date:
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: Tessa Jowell BRAIN MATRIX - Platform Study
- Study Title: A British feasibility study of molecular stratification and targeted therapy to optimize the clinical management of patients with glioma by enhancing clinical outcomes, Reducing avoidable toxicity, improving management of post-operative residual & recurrent disease and improving survivorship - Platform Study
- Study Phase:
- Sponsor: Cancer Research UK
- End Date: 01/03/2025
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (The ACTION Study)
- Study Title: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
- Study Phase: Phase 3
- Sponsor: Chimerix Inc.
- End Date:
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa:
- Study Title: PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.
- Study Phase: Phase 2
- Sponsor: Glasgow Clinical Trials Unit (University of Glasgow & Greater Glasgow & Clyde Health Board),NHS Greater Glasgow and Clyde Healthboard
- End Date:
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: ARISTOCRAT
- Study Title: A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma
- Study Phase: Phase 2
- Sponsor: University of Birmingham
- End Date: 01/08/2025
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: APPROACH
- Study Title: Analysis of Proton vs. Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health
- Study Phase: Not Applicable
- Sponsor: University of Leeds
- End Date:
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: BRIOChe
- Study Title: Brain Re-Irradiation Or Chemotherapy: A Phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
- Study Phase: Phase 2
- Sponsor: University of Leeds
- End Date: 31/08/2026
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: Assessing Treatment response in Glioblastoma (GBM) multiforme by MRI
- Study Title: Novel MRI methods to understand the mechanism of treatment response and resistance in Glioblastoma multiforme (GBM): An MRI study
- Study Phase: Phase 2
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Brain Cancer
- Principal Investigator: Mr Simon Shamas
- Project Acronym: Neurotoxicity of immune checkpoint inhibitor therapy
- Study Title: Neurotoxicity of immune checkpoint inhibitor therapy: A UK-wide case series
- Study Phase: Not Applicable
- Sponsor: Cardiff and Vale NHS Trust
- End Date:
- Status: Open
Research for Breast Cancer
-
- Cancer type: Breast Cancer
- Principal Investigator: Dr Helen Innes
- Project Acronym: J2J-MC-JZLH / EMBER-4 / Imlunestrant for ER+, HER2- Early Breast Cancer
- Study Title: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
- Study Phase: Phase 3
- Sponsor: Eli Lilly and Company Ltd - UK
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: PARABLE
- Study Title: PARABLE: Proton beam therapy in patients with breast cancer: evaluating early and late effects
- Study Phase: Not Applicable
- Sponsor: Institute of Cancer Research
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Dr Shaveta Mehta
- Project Acronym: ATNEC
- Study Title: ATNEC–Axillary management in T1?3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEoadjuvant Chemotherapy
- Study Phase: Pilot/Feasibility
- Sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
- End Date: 28/02/2030
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: TROPION-05
- Study Title: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Study Phase: Phase 3
- Sponsor: AstraZeneca
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: EP0062-101 - Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
- Study Title: A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability ,Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
- Study Phase: Phase 1
- Sponsor: Ellipses Pharma Limited
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: HER2-RADiCAL
- Study Title: The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer
- Study Phase:
- Sponsor: Institute of Cancer Research
- End Date: 28/02/2030
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: Elacestrant and Abemaciclib in brain metastases from breast cancer
- Study Title: AN OPEN-LABEL MULTICENTER PHASE 2 STUDY, WITH A SAFETY RUN-IN PHASE, OF ELACESTRANT AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB IN WOMEN AND MEN WITH BRAIN METASTASIS FROM ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE BREAST CANCER (ELECTRA)
- Study Phase: Phase 2
- Sponsor: Stemline Therapeutics, Inc.
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: ELEVATE
- Study Title: A Phase 1b/2, Open-label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
- Study Phase: Phase 1/2
- Sponsor: Stemline Therapeutics, Inc.
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: SAFE-DE
- Study Title: Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
- Study Phase:
- Sponsor: The Royal Marsden NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: TRAK-ER
- Study Title: A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER positive HER2 negative breast cancer
- Study Phase: Phase 2
- Sponsor: The Royal Marsden NHS Foundation Trust
- End Date: 03/09/2030
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: OPTIMA
- Study Title: Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis
- Study Phase: Phase 3
- Sponsor: University College London
- End Date: 31/12/2024
- Status: Open
-
- Cancer type: Breast Cancer
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: 3 Pillars
- Study Title: 3 Pillars – The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole, trastuzumab plus tucatinib as neoadjuvant treatment for ER-positive, HER2-positive early breast cancer
- Study Phase: Phase II
- Sponsor: University of Liverpool
- End Date:
- Status: Open
Research for Colorectal Cancer
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Amir Montazeri
- Project Acronym: BNT122-01 BioNTech SE Colorectal Cancer 4781/0016
- Study Title: A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
- Study Phase: Phase 2
- Sponsor: BioNTech SE
- End Date:
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Amir Montazeri
- Project Acronym: APHRODITE
- Study Title: A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer.
- Study Phase:
- Sponsor: University of Leeds
- End Date: 30/04/2027
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Amir Montazeri
- Project Acronym: ARTEMIS
- Study Title: Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery
- Study Phase: Phase II
- Sponsor: University of Leeds
- End Date:
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Amir Montazeri
- Project Acronym: FOxTROT Platform
- Study Title: FOxTROT: Personalising neo-adjuvant Chemotherapy in Locally advanced but operable colon cancer. A randomised trial programme.
- Study Phase: Phase 3
- Sponsor: University of Leeds
- End Date: 30/11/2029
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Amir Montazeri
- Project Acronym: How do patients make decisions about rectal cancer treatment?
- Study Title: How do patients make decisions about rectal cancer treatment?
- Study Phase:
- Sponsor: University of Leeds
- End Date: 30/04/2027
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Dr Rajaram Sripadam
- Project Acronym: OnCoRe
- Study Title: Oncological Outcomes after Clinical Complete Response in Patients with Rectal Cancer
- Study Phase:
- Sponsor: The Christie NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Colorectal Cancer
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: PINCER- Platform Study for Solid Organ Cancers
- Study Title: Temporal mapping of the tumour microenvironment in colorectal liver metastases
- Study Phase:
- Sponsor: University of Liverpool
- End Date:
- Status: Open
Research for Gynaecological Cancer
-
- Cancer type: Gynaecological Cancer
- Principal Investigator: Dr Danielle Shaw
- Project Acronym: VALTIVE1
- Study Title: VALTIVE1: Validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors: Optimising the design of a subsequent randomised discontinuation trial
- Study Phase:
- Sponsor: Manchester University NHS Foundation Trust (MFT)
- End Date: 31/10/2025
- Status: Open
-
- Cancer type: Gynaecological Cancer
- Principal Investigator: Dr Rosie Lord
- Project Acronym: ACTOv
- Study Title: Adaptive ChemoTherapy for Ovarian cancer: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer
- Study Phase: Phase 2
- Sponsor: University College London
- End Date:
- Status: Open
Research for Head & Neck Cancer
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Aditya Shenoy
- Project Acronym: Best-Of
- Study Title: Phase III study assessing the 'Best-Of' radiotherapy compared to the 'Best-Of' surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma
- Study Phase:
- Sponsor: EORTC - European Organisation for Research and Treatment of Cancer
- End Date: 01/01/2026
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Aditya Shenoy
- Project Acronym: PATHOS
- Study Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer
- Study Phase: Phase 2/3
- Sponsor: Velindre NHS Trust
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Caroline Brammer
- Project Acronym: PETNECK 2 - Feasibility Study and RCT, Version 1.0, 10-May-2021
- Study Title: PETNECK 2: PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head and neck cancer
- Study Phase:
- Sponsor: University of Birmingham
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Heulwen Sheldrick
- Project Acronym: Exploring the unmet needs of adult carers supporting a family member or friend with Head and Neck Cancer (HNC), who are 75 years and above.
- Study Title: Exploring the unmet needs of adult carers supporting a family member or friend with Head and Neck Cancer (HNC), who are 75 years and above.
- Study Phase:
- Sponsor: University of Liverpool
- End Date: 30/09/2025
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: QB46C-H08
- Study Title: A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.
- Study Phase: Phase 2
- Sponsor: QBiotics Group Limited
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Lynda Appleton
- Project Acronym: Respiratory-Swallow Training in Head and Neck Cancer
- Study Title: Development and feasibility of a respiratory-swallow training intervention to improve swallow function for people with head and neck cancer (ReST-HN)
- Study Phase: Not Applicable
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Dr Rachel Brooker
- Project Acronym: PROTIS
- Study Title: PROton beam Therapy versus Intensity-modulated radiotherapy for Sinonasal cancer
- Study Phase: Not Applicable
- Sponsor: The Christie NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: A Phase 2 study of BNT113 in HPV16+ HNSCC patients expressing PD-L1
- Study Title: An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1.
- Study Phase: Phase 2
- Sponsor: BioNTech SE
- End Date: 01/07/2028
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: PEMDA-HN
- Study Title: An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Study Phase: Phase II
- Sponsor: Flamingo Therapeutics
- End Date:
- Status: Open
-
- Cancer type: Head & Neck Cancer
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: TARGET HEAD AND NECK
- Study Title: Tissue analysis for stratifying therapy in head and neck diseases
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
Research for Leukaemia
-
- Cancer type: Leukaemia
- Principal Investigator: Dr Arpad (Gabe) Toth
- Project Acronym: Biomarker Driven Antifungal Stewardship: The BioDriveAFS Trial. V1.0
- Study Title: Biomarker Driven Antifungal Stewardship (BioDriveAFS) in Acute Leukaemia – a Multi-Centre Randomised Controlled Trial to Assess Clinical and Cost Effectiveness
- Study Phase:
- Sponsor: Hull University Teaching Hospitals NHS Trust
- End Date:
- Status: Open
-
- Cancer type: Leukaemia
- Principal Investigator: Dr Arpad (Gabe) Toth
- Project Acronym: ALLTogether1
- Study Title: ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
- Study Phase: Phase 3
- Sponsor: Karolinska University Hospital
- End Date: 30/06/2033
- Status: Open
-
- Cancer type: Leukaemia
- Principal Investigator: Dr Vikram Singh
- Project Acronym: STATIC
- Study Title: A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
- Study Phase: Phase 3
- Sponsor: University of Leeds
- End Date:
- Status: Open
-
- Cancer type: Leukaemia
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: UK CLL Biobank study
- Study Title: UK CLL Biobank study
- Study Phase:
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Leukaemia
- Principal Investigator: Sarah Watmough
- Project Acronym: PROPEL
- Study Title: PROPEL: Evaluation of PeRsOnalised PrEhabilitation in people with acute myeloid Leukaemia
- Study Phase:
- Sponsor: University of Warwick
- End Date:
- Status: Open
Research for Liver Cancer
-
- Cancer type: Liver Cancer
- Principal Investigator: Dr Olusola Faluyi
- Project Acronym: ABC-12
- Study Title: Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine
- Study Phase: Phase 2
- Sponsor: The Christie NHS Foundation Trust
- End Date:
- Status: Open
Research for Lung Cancer
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Anoop Haridass
- Project Acronym: SBRT ± Pembrolizumab in patients with Unresected Stage I or II NSCLC
- Study Title: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
- Study Phase: Phase 3
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date: 11/04/2026
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Carles Escriu
- Project Acronym: LATIFY
- Study Title: A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
- Study Phase: Phase 3
- Sponsor: AstraZeneca
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Carles Escriu
- Project Acronym: MOMENT (Met nOn sMall cEll caNcer regisTry)
- Study Title: Disease Registry on Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Skipping Alterations / MOMENT ((Met nOn sMall cEll caNcer regisTry))
- Study Phase:
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Carles Escriu
- Project Acronym: MK3475-D46
- Study Title: An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
- Study Phase: Phase 3
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Carles Escriu
- Project Acronym: Brigatinib-5007
- Study Title: A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-Authorisation Safety Study
- Study Phase:
- Sponsor: Takeda
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Carles Escriu
- Project Acronym: CONCORDE
- Study Title: A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer
- Study Phase: Phase 1
- Sponsor: University of Leeds
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Jonathan Heseltine
- Project Acronym: Furmo-004
- Study Title: A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS
- Study Phase: Phase 3
- Sponsor: ArriVent BioPharma, Inc.
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Matthew Howell
- Project Acronym: MK2870-004
- Study Title: A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations
- Study Phase: Phase III
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Tony Pope
- Project Acronym: REFINE-Lung
- Study Title: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design
- Study Phase: Phase 3
- Sponsor: Imperial College London
- End Date: 31/05/2027
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Tony Pope
- Project Acronym: ASSESS-Meso (TILT) cohort study
- Study Title: A prospective observational cohort study examining the natural history of mesothelioma, exploring potential biomarkers and factors that may predict outcome, as well as providing a resource for future trials within a cohort. TILT Cohort study
- Study Phase:
- Sponsor: North Bristol NHS Trust
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Tony Pope
- Project Acronym: LAGOON Trial
- Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer (SCLC) Patients (LAGOON Trial)
- Study Phase:
- Sponsor: PharmaMar SA
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Dr Tony Pope
- Project Acronym: TOURIST, (PRINCE,) a platform for multiple randomised trials using advanced radiotherapy techniques to establishes the utility of thoracic radiotherapy in the treatment of stage IV NCSLC.
- Study Title: TOURIST, a platform for multiple randomised trials using advanced radiotherapy techniques to establishes the utility of thoracic radiotherapy in the treatment of stage IV NCSLC.
- Study Phase:
- Sponsor: The Christie NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: LuCa-MERIT-1
- Study Title: LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
- Study Phase: Phase 1
- Sponsor: BioNTech SE
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: TargetLung
- Study Title: Tissue analysis for stratifying therapy in proliferative lung diseases
- Study Phase:
- Sponsor: University Hospital Southampton NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Lung Cancer
- Principal Investigator: Prof Michael Brada
- Project Acronym: MRI in Lung Cancer
- Study Title: MRI in Lung Cancer; a prospective study
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
Research for Lymphoma
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Arvind Arumainathan
- Project Acronym: WMUK Registry
- Study Title: The Rory Morrison Registry - Waldenström's Macroglobulinemia Registry (WMUK)
- Study Phase:
- Sponsor: University College London
- End Date: 01/06/2032
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Arvind Arumainathan
- Project Acronym: PROCLIPI
- Study Title: Multicenter Observational Prospective Study For The Identification Of Prognostic Factors In Patients With Mycosis Fungoides/Sezary Syndrome: Proposal For An International Prognostic Index For Cutaneous Lymphoma
- Study Phase:
- Sponsor: University Hospitals Birmingham NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Arvind Arumainathan
- Project Acronym: PETReA
- Study Title: PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
- Study Phase: Phase 3
- Sponsor: University of Liverpool
- End Date: 01/11/2025
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: OptiMATE
- Study Title: Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial
- Study Phase: Phase 3
- Sponsor: Klinikum der Landeshauptstadt Stuttgart
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: MK-4280A vs Physician’s Choice Chemotherapy in PD-1/L1-refractory R/R cHL
- Study Title: A Phase 3 Randomized Clinical Study of MK?4280A (coformulated favezelimab [MK?4280] plus pembrolizumab [MK?3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma
- Study Phase: Phase 3
- Sponsor: Merck Sharpe & Dohme - MSD
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: T-cell Project 2.0_Version 1.0 – June 18, 2018
- Study Title: PROSPECTIVE OBSERVATIONAL INTERNATIONAL COHORT STUDY OF PATIENTS WITH NEWLY DIAGNOSED PERIPHERAL T CELL LYMPHOMA.
- Study Phase:
- Sponsor: Nottingham University Hospitals NHS Trust
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: NX-5948 in Adults with Relapsed/Refractory B-cell Malignancies
- Study Title: A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
- Study Phase: Phase 1
- Sponsor: Nurix Therapeutics Inc
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: Primary vitreoretinal lymphoma (PVRL)
- Study Title:
- Study Phase:
- Sponsor: St Vincents Hospital Sydney
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Jeffrey Smith
- Project Acronym: PRiZM+
- Study Title: PRiZM+: A phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary CNS lymphoma
- Study Phase: Phase 2
- Sponsor: University of Birmingham
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Matt Wells
- Project Acronym: CARAMEL
- Study Title: Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients with Previously Untreated Mantle Cell Lymphoma
- Study Phase: Phase 2
- Sponsor: University College London
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Dr Matt Wells
- Project Acronym: ZEBRA
- Study Title: Zanubrutinib plus rituximab (Zanu-R) as fixed duration, early intervention versus observation for patients with indolent mantle cell lymphoma: a randomised phase II clinical trial
- Study Phase: Phase 2
- Sponsor: University College London
- End Date: 01/12/2028
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: M20-638 (EPCORE FL-1): Relapsed/Refractory Follicular Lymphoma: Epcoritamab in Combination with R2
- Study Title: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
- Study Phase: Phase 3
- Sponsor: Abbvie Inc
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: REFRACT
- Study Title: Relapsed Follicular lymphoma Randomised trial Against standard ChemoTherapy (REFRACT): A randomised phase II trial of investigator choice standard therapy versus sequential novel therapy experimental arms
- Study Phase: Phase 2
- Sponsor: University of Birmingham
- End Date:
- Status: Open
-
- Cancer type: Lymphoma
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: NAVAL-1
- Study Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
- Study Phase: Phase 2
- Sponsor: Viracta Therapeutics, Inc
- End Date: 31/12/2026
- Status: Open
Research for Melanoma
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: IDE009
- Study Title: (NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA
- Study Phase: Phase II
- Sponsor: Ideaya Biosciences, Inc
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: IDE196-002
- Study Title: IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
- Study Phase: Phase II/III
- Sponsor: Ideaya Biosciences, Inc
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: Phase 1/2 Study of IMC-F106C in Advanced PRAME-Positive Cancers
- Study Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
- Study Phase: Phase 1/2
- Sponsor: Immunocore Limited
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: PRISM-MEL-301
- Study Title: A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Study Phase: Phase III
- Sponsor: Immunocore Limited
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: Phase 1/2 Study of RP1 +/- other therapies in solid tumours
- Study Title: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
- Study Phase: Phase 1/2
- Sponsor: Replimune Ltd
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: The Prospective Ocular Melanoma Natural History (OMNi) Study
- Study Title: A Prospective Natural History Study in Uveal Melanoma.
- Study Phase:
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Joseph Sacco
- Project Acronym: TebeMRD: Tebentafusp in MRD Melanoma
- Study Title: A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma with Molecular Relapsed Disease
- Study Phase: Phase 2
- Sponsor: University of Oxford
- End Date:
- Status: Open
-
- Cancer type: Melanoma
- Principal Investigator: Dr Laura Cossar
- Project Acronym: LATENT
- Study Title: LATe TreatmENT related Toxicity in Melanoma (LATENT)
- Study Phase: Not Applicable
- Sponsor: The Royal Marsden NHS Foundation Trust
- End Date:
- Status: Open
Research for Multiple Cancer Types
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Kate Parker
- Project Acronym: Exploring the experiences of people who present with metastatic spinal cord compression with a malignancy of unknown origin.
- Study Title: Exploring the experiences of people who present with metastatic spinal cord compression with a malignancy of unknown origin.
- Study Phase:
- Sponsor: Lancaster University
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Anoop Haridass
- Project Acronym: E2-RADIatE (EORTC 1811)
- Study Title: E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
- Study Phase:
- Sponsor: EORTC - European Organisation for Research and Treatment of Cancer
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Eliyaz Ahmed
- Project Acronym: EGG-CUP
- Study Title: Enabling Genomic Testing in Cancer of Unknown Primary (EGG-CUP)
- Study Phase: Not Applicable
- Sponsor: The Christie NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: ICI Genetics
- Study Title: Identification of genetic factors that predispose to immune checkpoint inhibitor toxicity
- Study Phase:
- Sponsor: University of Birmingham
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Laura Cossar
- Project Acronym: Molecular Genetics of Adverse Drug Reactions (MOLGEN)
- Study Title: Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies
- Study Phase:
- Sponsor: Newham University Hospital NHS Trust,University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Laura Cossar
- Project Acronym: HYST
- Study Title: Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- Study Phase:
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Lynda Appleton
- Project Acronym: IMPACT
- Study Title: IMmunotherapy and PAlliative Care Trajectories (IMPACT): A mixed methods study mapping illness trajectories for people with advanced cancer receiving immunotherapy treatment to identify palliative care need
- Study Phase:
- Sponsor: Lancaster University
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Lynda Appleton
- Project Acronym: REAP
- Study Title: Reducing Emergency Admissions for Patients with Cancer Complications and/or Co-morbidities
- Study Phase: Study
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Marc Rea
- Project Acronym: MRI Screening with AI; A Prospective Study
- Study Title: Feasibility of fast imaging methods for whole body AI–assisted screening in MRI
- Study Phase: Pilot/Feasibility
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Seamus Coyle
- Project Acronym: POST study: Palliative Care and Oncology Survey on Terminology v1
- Study Title: What do individuals known to palliative care and oncology services think about the terminology used to describe them?
- Study Phase:
- Sponsor: Our Lady's Hospice & Care Service
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Seamus Coyle
- Project Acronym: Metabolic changes at end of life
- Study Title: Investigation of biological changes in cancer towards the end of life
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Dr Seamus Coyle
- Project Acronym: The iLIVE Project
- Study Title: The iLIVE project: Live well, die well. A research programme to support living until the end.
- Study Phase:
- Sponsor: University of Liverpool
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Louise Turtle
- Project Acronym: National Radiotherapy Patient Experience Survey
- Study Title: National Radiotherapy Patient Experience Survey
- Study Phase:
- Sponsor: Birmingham City University
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: CCP-Cancer UK
- Study Title: CCP-Cancer UK: Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK) – a prospective companion study for patients with Cancer and COVID-19.
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Carlo Palmieri
- Project Acronym: Add-Aspirin
- Study Title: A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
- Study Phase: Phase 3
- Sponsor: University College London
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Christian Ottensmeier
- Project Acronym: Target Vaccination Version 1
- Study Title: Evaluation of response to routine vaccination to assess immunocompetence in patients with cancer
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: Ceralasertib (AZD6738)
- Study Title: A Phase I, Open-label Study to Assess the Absolute Bioavailability of Ceralasertib (AZD6738) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Ceralasertib in Patients with Non-small Cell Lung Cancer, Ovarian Cancer, or Endometrial Cancer
- Study Phase: Phase I
- Sponsor: AstraZeneca
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: A Phase I/IIa Trial of HTL0039732 in Participants with Advanced Solid Tumours
- Study Title: A Cancer Research UK Phase I/IIa Trial of HTL0039732, given Orally as Monotherapy and in Combination with Immunotherapy or Other Approved Therapies in Participants with Advanced Solid Tumours
- Study Phase: Phase I/II
- Sponsor: Cancer Research UK
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: DETERMINE
- Study Title: Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly defined Indications using a National Evaluation platform trial
- Study Phase: Phase 2/3
- Sponsor: Cancer Research UK
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: ATTAINMENT
- Study Title: A modular, multi-arm, first in human trial to evaluate the safety and tolerability of MDX-124 alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies
- Study Phase: Phase 1
- Sponsor: Medannex Limited
- End Date:
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: TARGET NATIONAL
- Study Title: Tumour Characterisation to Guide Experimental Targeted Therapy - National Expansion
- Study Phase: Experimental Medicine
- Sponsor: The Christie NHS Foundation Trust
- End Date: 01/01/2026
- Status: Open
-
- Cancer type: Multiple Cancer Types
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: LECMC Biomarker Discovery Programme & Prospective Sample Collection
- Study Title: Liverpool Experimental Cancer Medicine Centre (LECMC) Biomarker Discovery Programme and Prospective Sample Collection
- Study Phase:
- Sponsor: University of Liverpool
- End Date: 31/03/2028
- Status: Open
Research for Multiple Sclerosis
-
- Cancer type: Multiple Sclerosis
- Principal Investigator: Dr Muhammad Saif
- Project Acronym: StarMS
- Study Title: A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.
- Study Phase: Phase 3
- Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
- End Date:
- Status: Open
Research for Myelodysplastic syndromes (MDS)
-
- Cancer type: Myelodysplastic syndromes (MDS)
- Principal Investigator: Dr Arpad (Gabe) Toth
- Project Acronym: Phase 3 Study of SY-1425 Plus Azacitidine in RARA-positive Higher-risk MDS
- Study Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
- Study Phase: Phase 3
- Sponsor: Syros Pharmaceuticals
- End Date:
- Status: Open
Research for Myelofibrosis
-
- Cancer type: Myelofibrosis
- Principal Investigator: Dr Nauman Butt
- Project Acronym: XPORT-MF-034
- Study Title: A Phase 1/2 Study of to evaluate safety and efficacy of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib, in treatment naïve patients with myelofibrosis
- Study Phase: Phase 1/2
- Sponsor: Karyopharm Therapeutics, Inc (USA)
- End Date:
- Status: Open
Research for Myeloma
-
- Cancer type: Myeloma
- Principal Investigator: Dr Gillian Brearton
- Project Acronym: NCRN443: PREAMBLE observational myeloma
- Study Title: PROSPECTIVE RESEARCH ASSESSMENT IN MULTIPLE MYELOMA: AN OBSERVATIONAL EVALUATION
- Study Phase:
- Sponsor: Bristol Myers Squibb
- End Date:
- Status: Open
-
- Cancer type: Myeloma
- Principal Investigator: Dr Gillian Brearton
- Project Acronym: HALO
- Study Title: A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
- Study Phase:
- Sponsor: Janssen Ltd.
- End Date:
- Status: Open
-
- Cancer type: Myeloma
- Principal Investigator: Dr Stephen Hawkins
- Project Acronym: MajesTEC-9
- Study Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
- Study Phase: Phase 3
- Sponsor: Janssen Ltd.
- End Date:
- Status: Open
-
- Cancer type: Myeloma
- Principal Investigator: Dr Stephen Hawkins
- Project Acronym: RADAR (UK-MRA Myeloma XV)
- Study Title: Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
- Study Phase: Phase 2/3
- Sponsor: University of Leeds
- End Date: 31/05/2029
- Status: Open
Research for Myeloproliferative Neoplasms (MPN)
-
- Cancer type: Myeloproliferative Neoplasms (MPN)
- Principal Investigator: Dr Nauman Butt
- Project Acronym: The UK-MPN-MF Registry
- Study Title: The UK Myeloproliferative Neoplasms Registry for Myelofibrosis
- Study Phase:
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Myeloproliferative Neoplasms (MPN)
- Principal Investigator: Dr Rachel Wells
- Project Acronym: MOSAICC Study (Version 1.0)
- Study Title: MyelOproliferative neoplasmS: An In-depth Case-Control (MOSAICC) study: A case-control study of patients with Myeloproliferative neoplasms and non-blood relative/friend controls.
- Study Phase:
- Sponsor: University of Aberdeen
- End Date: 30/06/2025
- Status: Open
Research for Other Blood Cancer
-
- Cancer type: Other Blood Cancer
- Principal Investigator: Dr Stella Williams
- Project Acronym: BGB-11417-301
- Study Title: A Phase 3, Open-label, Randomized Study of BGB-11417 plus Zanubrutinib Compared with Venetoclax plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
- Study Phase:
- Sponsor: BeiGene Ltd
- End Date:
- Status: Open
-
- Cancer type: Other Blood Cancer
- Principal Investigator: Prof Andy Pettitt
- Project Acronym: M19-388 Venetoclax Extension Study
- Study Title: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
- Study Phase: Phase 3
- Sponsor: Abbvie Inc
- End Date: 31/05/2025
- Status: Open
Research for Prostate Cancer
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Azman Ibrahim
- Project Acronym: IP2 - ATLANTA
- Study Title: ATLANTA - Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms
- Study Phase:
- Sponsor: Imperial College London
- End Date:
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: IRONMAN Registry Study
- Study Title: Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)
- Study Phase:
- Sponsor: Guy's and St Thomas' NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: PEARLS study
- Study Title: A Phase II/III trial of Primary radiotherapy for Androgen sensitive Prostate cancer patients with Lymph nodes
- Study Phase: Phase 2/3
- Sponsor: Institute of Cancer Research
- End Date: 31/12/2027
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: ADAPT-P
- Study Title: Impact of apalutamide in metastatic hormone sensitive prostate cancer patients, a multi-centre prospective observational study
- Study Phase:
- Sponsor: The Royal Marsden NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: PARADIGM
- Study Title: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer
- Study Phase:
- Sponsor: University College London
- End Date:
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Isabel Syndikus
- Project Acronym: RECOmMEnD ‘A prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients treated as part of triplet therapy with Darolutamide’
- Study Title: RECOmMEnD ‘A prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients treated as part of triplet therapy with Darolutamide’
- Study Phase:
- Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust
- End Date:
- Status: Open
-
- Cancer type: Prostate Cancer
- Principal Investigator: Dr Shaun Tolan
- Project Acronym: PACE-NODES
- Study Title: PACE-NODES: A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT
- Study Phase:
- Sponsor: Institute of Cancer Research
- End Date:
- Status: Open
Research for Sarcoma
-
- Cancer type: Sarcoma
- Principal Investigator: Dr Nasim Ali
- Project Acronym: STRASS 2 (1809-STBSG)
- Study Title: A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma
- Study Phase: Phase 3
- Sponsor: EORTC - European Organisation for Research and Treatment of Cancer
- End Date: 01/04/2028
- Status: Open
-
- Cancer type: Sarcoma
- Principal Investigator: Dr Nasim Ali
- Project Acronym: PM1183-C-010-22
- Study Title: Randomized, Controlled, Open-label, Phase IIb/III Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Patients with Metastatic Leiomyosarcoma
- Study Phase: Phase 2/3
- Sponsor: PharmaMar SA
- End Date:
- Status: Open
-
- Cancer type: Sarcoma
- Principal Investigator: Dr Nasim Ali
- Project Acronym: ICONIC
- Study Title: Improving outcomes through collaboration in osteosarcoma
- Study Phase:
- Sponsor: University College London
- End Date:
- Status: Open
-
- Cancer type: Sarcoma
- Principal Investigator: Dr Nasim Ali
- Project Acronym: FaR-RMS
- Study Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
- Study Phase: Phase 1/2
- Sponsor: University of Birmingham
- End Date: 17/09/2030
- Status: Open
-
- Cancer type: Sarcoma
- Principal Investigator: Dr Nasim Ali
- Project Acronym: rEECur
- Study Title: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
- Study Phase: Phase 2/3
- Sponsor: University of Birmingham
- End Date: 25/02/2025
- Status: Open
Research for Upper GI
-
- Cancer type: Upper GI
- Principal Investigator: Dr Alia Alchawaf
- Project Acronym: ViSON
- Study Title: VOLATILE ORGANIC COMPOUNDS AS BREATH BIOMARKERS IN SQUAMOUS OESOPHAGEAL NEOPLASMS (ViSON)
- Study Phase:
- Sponsor: Imperial College London
- End Date:
- Status: Open
-
- Cancer type: Upper GI
- Principal Investigator: Dr Chinnamani Eswar
- Project Acronym: PROTIEUS
- Study Title: A Randomised Phase 2 Trial Comparing Proton versus Photon Based Neoadjuvant Chemoradiation, followed by Adjuvant Immunotherapy, in Oesophageal Cancer.
- Study Phase: Not Applicable
- Sponsor: University College London
- End Date:
- Status: Open
-
- Cancer type: Upper GI
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: CRUK HUNTER Accelerator – delivering immunotherapy for liver cancer
- Study Title: HUNTER: Hepatocellular Carcinoma Expediter Network - created to define the hepatocellular carcinoma immune environment, the key mechanisms and biomarkers, and to develop the pre-clinical models needed, to deliver immunotherapy to patients with liver cancer
- Study Phase:
- Sponsor: Newcastle Upon Tyne NHS Foundation Trust
- End Date: 30/11/2025
- Status: Open
-
- Cancer type: Upper GI
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: PRIMUS 001
- Study Title: PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation
- Study Phase: Phase 2
- Sponsor: NHS Greater Glasgow and Clyde Healthboard
- End Date: 31/07/2025
- Status: Open
-
- Cancer type: Upper GI
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: TACE-3
- Study Title: TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC
- Study Phase: Phase 2/3
- Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
- End Date: 30/09/2025
- Status: Open
-
- Cancer type: Upper GI
- Principal Investigator: Prof Daniel Palmer
- Project Acronym: HPB Tissue Sampling Study
- Study Title: Proteomic and genomic assessment of hepatopancreaticobiliary cancers
- Study Phase: Not Applicable
- Sponsor: University of Liverpool
- End Date:
- Status: Open
